China's Blood Transfusion Technology Transferred To Laos

China's Blood Transfusion Technology Transferred To Laos

Since cooperating with the Lao National Red Cross Blood Center (hereinafter referred to as the "Blood Center"), the blood transfusion technology from Nanjing, Jiangsu Province has embarked on a special life-supporting journey. The messengers are blood filtration white blood cell technology and blood component preparation technology.

Blood transfusion is an important measure to rescue critically ill patients and treat acute blood loss and severe chronic anemia. Before blood transfusion, white blood cells in the blood need to be filtered out to reduce the immune response to blood transfusion and ensure the safety of human blood transfusion. In our country, this operating procedure has been promoted for decades. However, in 2018, when Shuangwei Biotech participated in an academic conference organized by the Blood Center, it was discovered that Laos still mainly transfuses whole blood, and has not yet carried out component transfusions, let alone leukocyte filtration of blood. Shuangwei Biotech realized that perhaps more people could benefit from the blood component processing technology accumulated over the past two decades.

In the 1990s, Shuangwei Biotech took the lead in developing Leukocyte Reduction Filter for Blood in China. Supporting the company's innovation capabilities is its annual R&D investment of more than 10 million yuan and its scientific research team of approximately 50 people. In 2020, Shuangwei Biotech applied to the Jiangsu Provincial Department of Science and Technology for the "Belt and Road" innovative cooperation project "Cooperative Development of Overseas Application of Blood Leukocyte Reduction Processing Technology", which was finally approved.

Shuangwei Biotech's cooperation with the blood center is not a simple product export, but to convey to them the concept of 'leukocyte reduction blood transfusion' component transfusion, and cooperate with the other party to develop blood leukocyte-removed processing technology and develop hardware conditions suitable for the preparation of blood components in Laos. Preparation technology and quality control standards, so that the Lao people can receive safe blood transfusions and protect their lives.

In the following two years, a series of blood component preparation technologies were transferred between Shuangwei Biotech and the blood center.

In order to improve the efficiency of filtering white blood cells in the blood, Shuangwei Biotech has surface-modified the filter membrane of the leukocyte reduction filter to improve the filtering effect of white blood cells during warm blood filtration. At the same time, soft-shell leukocyte reduction filters are produced, which solves the problem of side leakage of centrifuged blood in hard-shell leukocyte reduction filters. Since the cooperation between the two parties, Shuangwei Biotech has developed 15 new products such as 350 ml blood component leukocyte reduction filters suitable for Laos' national conditions, and developed fully automatic soft/hard shell filter welding equipment with independent intellectual property rights.

Shuangwei Biotech also introduced China's blood management standards to the blood center, especially the blood component quality monitoring guidelines, the preparation and quality control of leukocyte-depleted mixed platelet concentrates, etc., and helped them establish blood component preparation business processes, including blood testing, blood management, quality manage standards and share with them important techniques for clinical evaluation.

Shuangwei Biotech hopes to use the technical capabilities accumulated over many years to increase the application rate of Lao component blood transfusion and leukocyte-depleted blood components. The mutual learning and mutual learning in cooperation also urge us to continuously iterate technology and adapt to changing market development needs. Shuangwei Biotech hopes to use the scientific and technological innovation of Chinese companies to provide more benefits to the lives and health of people in countries along the Belt and Road Initiative.

Today, Shuangwei Biotech's leukocyte reduction filter and blood transfusion equipment products have been promoted to more than 30 countries and regions including Brazil, Russia, and other BRICS countries as well as countries co-building the "Belt and Road".